Arch Biopartners ((TSE:ARCH)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arch Biopartners is conducting a Phase 2 global study titled ‘Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery.’ The study aims to assess the effectiveness of LSALT Peptide in reducing the incidence of AKI in patients post-cardiac surgery, a significant concern due to its potential impact on patient recovery and healthcare costs.
The intervention being tested is LSALT Peptide, an experimental drug administered intravenously. It aims to prevent AKI by inhibiting leukocyte recruitment, potentially reducing inflammation and kidney damage during surgery.
This study is interventional with a randomized, single-group assignment. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocation. The primary purpose is prevention, focusing on reducing the incidence of AKI.
The study began on May 18, 2023, with an estimated primary completion date in 2025. The last update was submitted on August 11, 2025, indicating ongoing progress and adherence to the timeline.
This update could positively influence Arch Biopartners’ stock performance, as successful results might enhance the company’s market position in the biotech industry. Investors may view this as a promising development, especially given the competitive landscape in AKI prevention and treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.